Colin Neate

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab

Daniel J. Lenihan, Thomas Suter, Melissa Brammer et al. · Annals of Oncology · 2011 · 122 citations · Full text

Pharmacy, Cardiology, Oncology +12

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

Marion van Mackelenbergh, Sibylle Loibl, Michael Untch et al. · Journal of Clinical Oncology · 2023 · 96 citations

Medicine, Oncology, Breast Oncology +16

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy

Pierre Squifflet, Everardo D. Saad, Sibylle Loibl et al. · Journal of Clinical Oncology · 2023 · 55 citations

Medicine, Biostatistics, Oncology +15

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension

J. A. Stakkestad, P. Lakatos, R Lorenc et al. · Clinical Rheumatology · 2008 · 46 citations

Dentistry, Pharmacotherapy, Oral Medicine In Older Adults +1

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): Additional results from the monthly oral therapy with ibandronate for osteoporosis intervention (MOTION) study

Ronald Emkey, Pierre D. Delmas, Michael A. Bolognese et al. · Clinical Therapeutics · 2009 · 32 citations

Pharmacy, Pharmacotherapy, Bone Augmentation +8